Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 1M | 0 | 2M | 4M |
| Gross Profit | -16K | 1M | 0 | 2M | 4M |
| Operating Income | -33M | -24M | -26M | -23M | -22M |
| EBITDA | -33M | -23M | -26M | -25M | -18M |
| Net Income | -27M | -18M | -20M | -19M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$35.04
+3.30% today
1Y Change
+123.45%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
vTv Therapeutics Inc. (VTVT) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $35.04 and up 123.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS 0.0%, free cash flow +0.2% with operating margin 0.0% and ROIC -39.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTVT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTVT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VTVT Max Drawdown
-32.06%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VTVT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.0M
+98.5% YoY
FY Net Income
-$13.0M
+32.2% YoY
Free Cash Flow
-$19.3M
-26.5% YoY
Revenue Growth
-100.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 1M | 0 | 2M | 4M |
| Gross Profit | -16K | 1M | 0 | 2M | 4M |
| Operating Income | -33M | -24M | -26M | -23M | -22M |
| EBITDA | -33M | -23M | -26M | -25M | -18M |
| Net Income | -27M | -18M | -20M | -19M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89M | 37M | 9M | 12M | 13M |
| Total Assets | 90M | 38M | 11M | 33M | 25M |
| Total Liabilities | 25M | 24M | 30M | 27M | 10M |
| Shareholder Equity | 64M | 12M | -25M | -11M | -10M |
| Total Debt | 0 | 169K | 529K | 716K | 932K |
| Net Debt | -89M | -37M | -9M | -11M | -12M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
19M
-26.6% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
19M
-26.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-74.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.